Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab.

NACompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Psoriasis
Interventions
DRUG

Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA]

40mg subcutaneously, every other week for 6 months

Trial Locations (1)

27516

UNC Dermatology Clinical Trials Unit, Chapel Hill

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AbbVie

INDUSTRY

lead

University of North Carolina, Chapel Hill

OTHER